All In Biotech

Drug Trial Radar · NCT05686759

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. in Post-liver Transplant Patients

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Apr 13, 2023

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients

Conditions

  • Hepatitis B

Interventions

  • Undiluted I.V.-Hepabig inj(GC5103)Biological

    undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit

  • Diluted I.V.-Hepabig inj(GC5103)Biological

    Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events occurred during clinical trialsTime frame: during 20 weeks post first Investigational product administration

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Inje University Haeundae Paik Hospital

    Busan, South Korea · Recruiting

  • Chungnam National University Hospital

    Daejeon, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea · Recruiting

  • Ajou University Medical Center

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Asan Medical Center

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.